Lars Jørgen Østergaard

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study. / EuroSIDA study.

In: Medicine (United States), Vol. 95, No. 40, e5020, 2016.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{28980b668baf4993bf4bfa8631dcc6d5,
title = "Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study",
abstract = "Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR <50copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL >50copies/mL. We included 285 subjects, 67% male, with median baseline CD4 530 cells, and 44 months with pVL ≤50copies/mL. The third drug in the previous regimen was ritonavir-boosted atazanavir (ATV/r) in 79 (28%), and another ritonavir-boosted protease inhibitor (PI/r) in 29 (10%). Ninety (32%) had previously failed with a PI. Proportions of people with virological success at 48/96/144 weeks were 90%/87%/88% (TLOVR) and 74%/67%/59% (snapshot analysis), respectively. The rates of VF were 8%/8%/6%. Rates of adverse events leading to study discontinuation were 0.4%/1%/2%. The multivariable adjusted analysis showed an association between VF and nadir CD4+ (hazard ratio [HR] 0.63 [95% confidence interval [CI]: 0.42-0.93] per 100 cells higher), time with pVL ≤50copies/mL (HR 0.87 [95% CI: 0.79-0.96] per 6 months longer), and previous failure with a PI (HR 2.78 [95% CI: 1.28-6.04]). Resistance selection at failure was uncommon. A switch to ATV + ABC/3TC in selected subjects with suppressed viremia was associated with low rates of VF and discontinuation due to adverse events, even in subjects not receiving ATV/r. The strategy might be considered in those with long-term suppression and no prior PI failure.",
keywords = "Atazanavir, HIV-1, Protease inhibitors: abacavir, Simplification antiretroviral therapy",
author = "Llibre, {Josep M.} and Alessandro Cozzi-Lepri and Court Pedersen and Matti Ristola and Marcelo Losso and Amanda Mocroft and Viktar Mitsura and Karolin Falconer and Fernando Maltez and Marek Beniowski and Vincenzo Vullo and Gamal Hassoun and Elena Kuzovatova and J{\'a}nos Szlavik and Anastasiia Kuznetsova and Stellbrink, {Hans J{\"u}rgen} and Claudine Duvivier and Simon Edwards and Kamilla Laut and Roger Paredes and M. Losso and M. Kundro and N. Vetter and R. Zangerle and I. Karpov and A. Vassilenko and Mitsura, {V. M.} and D. Paduto and N. Clumeck and {De Wit}, S. and M. Delforge and E. Florence and L. Vandekerckhove and M{\o}ller, {N. F.} and C. Pedersen and L. Ostergaard and Nielsen, {L. N.} and R. Schmidt and J. Bruun and M. Gutierrez and R. Weber and Johnson, {A. M.} and S. Edwards and Johnson, {M. A.} and J. Weber and L. Peters and Fischer, {A. H.} and A. Bojesen and D. Kristensen and Larsen, {J. F.} and {EuroSIDA study}",
note = "Publisher Copyright: Copyright {\textcopyright} 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2016",
doi = "10.1097/MD.0000000000005020",
language = "English",
volume = "95",
journal = "Medicine (Baltimore)",
issn = "0025-7974",
publisher = "Wolters Kluwer Health, Inc.",
number = "40",

}

RIS

TY - JOUR

T1 - Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression

T2 - A prospective cohort study

AU - Llibre, Josep M.

AU - Cozzi-Lepri, Alessandro

AU - Pedersen, Court

AU - Ristola, Matti

AU - Losso, Marcelo

AU - Mocroft, Amanda

AU - Mitsura, Viktar

AU - Falconer, Karolin

AU - Maltez, Fernando

AU - Beniowski, Marek

AU - Vullo, Vincenzo

AU - Hassoun, Gamal

AU - Kuzovatova, Elena

AU - Szlavik, János

AU - Kuznetsova, Anastasiia

AU - Stellbrink, Hans Jürgen

AU - Duvivier, Claudine

AU - Edwards, Simon

AU - Laut, Kamilla

AU - Paredes, Roger

AU - Losso, M.

AU - Kundro, M.

AU - Vetter, N.

AU - Zangerle, R.

AU - Karpov, I.

AU - Vassilenko, A.

AU - Mitsura, V. M.

AU - Paduto, D.

AU - Clumeck, N.

AU - De Wit, S.

AU - Delforge, M.

AU - Florence, E.

AU - Vandekerckhove, L.

AU - Møller, N. F.

AU - Pedersen, C.

AU - Ostergaard, L.

AU - Nielsen, L. N.

AU - Schmidt, R.

AU - Bruun, J.

AU - Gutierrez, M.

AU - Weber, R.

AU - Johnson, A. M.

AU - Edwards, S.

AU - Johnson, M. A.

AU - Weber, J.

AU - Peters, L.

AU - Fischer, A. H.

AU - Bojesen, A.

AU - Kristensen, D.

AU - Larsen, J. F.

AU - EuroSIDA study

N1 - Publisher Copyright: Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2016

Y1 - 2016

N2 - Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR <50copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL >50copies/mL. We included 285 subjects, 67% male, with median baseline CD4 530 cells, and 44 months with pVL ≤50copies/mL. The third drug in the previous regimen was ritonavir-boosted atazanavir (ATV/r) in 79 (28%), and another ritonavir-boosted protease inhibitor (PI/r) in 29 (10%). Ninety (32%) had previously failed with a PI. Proportions of people with virological success at 48/96/144 weeks were 90%/87%/88% (TLOVR) and 74%/67%/59% (snapshot analysis), respectively. The rates of VF were 8%/8%/6%. Rates of adverse events leading to study discontinuation were 0.4%/1%/2%. The multivariable adjusted analysis showed an association between VF and nadir CD4+ (hazard ratio [HR] 0.63 [95% confidence interval [CI]: 0.42-0.93] per 100 cells higher), time with pVL ≤50copies/mL (HR 0.87 [95% CI: 0.79-0.96] per 6 months longer), and previous failure with a PI (HR 2.78 [95% CI: 1.28-6.04]). Resistance selection at failure was uncommon. A switch to ATV + ABC/3TC in selected subjects with suppressed viremia was associated with low rates of VF and discontinuation due to adverse events, even in subjects not receiving ATV/r. The strategy might be considered in those with long-term suppression and no prior PI failure.

AB - Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR <50copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL >50copies/mL. We included 285 subjects, 67% male, with median baseline CD4 530 cells, and 44 months with pVL ≤50copies/mL. The third drug in the previous regimen was ritonavir-boosted atazanavir (ATV/r) in 79 (28%), and another ritonavir-boosted protease inhibitor (PI/r) in 29 (10%). Ninety (32%) had previously failed with a PI. Proportions of people with virological success at 48/96/144 weeks were 90%/87%/88% (TLOVR) and 74%/67%/59% (snapshot analysis), respectively. The rates of VF were 8%/8%/6%. Rates of adverse events leading to study discontinuation were 0.4%/1%/2%. The multivariable adjusted analysis showed an association between VF and nadir CD4+ (hazard ratio [HR] 0.63 [95% confidence interval [CI]: 0.42-0.93] per 100 cells higher), time with pVL ≤50copies/mL (HR 0.87 [95% CI: 0.79-0.96] per 6 months longer), and previous failure with a PI (HR 2.78 [95% CI: 1.28-6.04]). Resistance selection at failure was uncommon. A switch to ATV + ABC/3TC in selected subjects with suppressed viremia was associated with low rates of VF and discontinuation due to adverse events, even in subjects not receiving ATV/r. The strategy might be considered in those with long-term suppression and no prior PI failure.

KW - Atazanavir

KW - HIV-1

KW - Protease inhibitors: abacavir

KW - Simplification antiretroviral therapy

UR - http://www.scopus.com/inward/record.url?scp=84995686661&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000005020

DO - 10.1097/MD.0000000000005020

M3 - Journal article

C2 - 27749561

AN - SCOPUS:84995686661

VL - 95

JO - Medicine (Baltimore)

JF - Medicine (Baltimore)

SN - 0025-7974

IS - 40

M1 - e5020

ER -